Drug discontinuation: Daptomycin Injection
FDA lists 2 presentations as To Be Discontinued. Companies: Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.).
- Published by source
- 2026-06-30
- First seen by Reality Radar
- 2026-10-22
- Last verified
- 2026-10-22
Affected
- Manufacturer
- Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)
- Products
- Daptomycin Injection
Whether your exact unit is affected depends on the model, serial number and region in the official notice.
What the official notice says
Risk: To Be Discontinued
Remedy / actions:
- Discontinuation of the manufacture of the drug
- Discontinuation of the manufacture of the drug; Marketed by Hikma Pharmaceuticals USA, Inc.
Is this affecting you?
Add what you own or use and Reality Radar will tell you when official changes match it — with evidence and next steps.
Sources
- openFDA Drug Shortages Tier A · official published 2026-06-30
Evidence ledger
Every piece of evidence we store is appended to a public hash chain, so later edits are detectable. Anyone can re-verify it.
| Entry | Kind | Observed | Evidence hash | Entry hash |
|---|---|---|---|---|
| #1053 | new | 2026-10-22 | 78853d8a853e…2d6ede | da83157be764…d8e7a2 |
Chain head: #1076 8ad5adc30b9b…88ce20